The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.
Clinical trial NCT00154323 · COMPLETED
Trial details
- NCT number
- NCT00154323
- Sponsor
- Novartis
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2003-01-01
- Primary completion
- 2006-01-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.